AI Multi-Omics Analytics Market Size, Revenue, Trend Report 2026 to 2035
What is AI Multi-Omics Analytics Market Size?
Global AI Multi-Omics Analytics Market Size is valued at USD 0.99 Bn in 2025 and is predicted to reach USD 11.67 Bn by the year 2035 at a 28.2% CAGR during the forecast period for 2026 to 2035.
AI Multi-Omics Analytics Market Size, Share & Trends Analysis Distribution by Offering (Software Platforms, Analytics Services), by Omics Data Type (Genomics, Transcriptomics, Proteomics, Metabolomics, Epigenomics, Others), by AI Technology (Machine Learning, Deep Learning, Others), by Application (Drug Discovery and Development, Biomarker Discovery, Clinical Diagnostics and Precision Medicine, Others), by End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Clinical Laboratories, Contract Research Organizations (CROs), Others) and Segment Forecasts, 2026 to 2035.
AI multi-omics analytics constitutes an advanced computational framework that integrates artificial intelligence with multi-layered biological datasets in order to generate deeper scientific and clinical insights. The approach combines data derived from genomics, transcriptomics, proteomics, metabolomics, epigenomics and related omics disciplines, thereby enabling a more comprehensive examination of biological systems than is achievable through single-omics analyses.
Through the application of machine learning, deep learning and associated artificial intelligence methodologies, these platforms are capable of detecting complex patterns, identifying candidate biomarkers, elucidating disease mechanisms and revealing biological relationships that may remain undetected by conventional statistical techniques. The technology facilitates the interpretation of large and heterogeneous datasets, supporting the translation of raw biological information into structured hypotheses and evidence-based conclusions.
AI multi-omics solutions are increasingly employed in drug discovery, precision medicine, clinical diagnostics and biomedical research. Within pharmaceutical development, they contribute to target identification, patient stratification and the analysis of treatment response. In clinical and research environments, they assist in refined disease characterisation and the formulation of personalised therapeutic strategies. As the volume and complexity of biological data continue to expand, AI multi-omics analytics is emerging as a significant instrument for the extraction of actionable knowledge from multi-dimensional biological information.
The market covers the development, deployment, and commercialisation of AI-powered multi-omics analytics solutions across pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinical laboratories, and contract research organisations (CROs). It brings together technology providers, genomics and life sciences companies, AI software developers, and research organisations working to make complex biological data easier to analyse and apply. The market also includes services that help organisations integrate different omics datasets, build analytical workflows, and generate meaningful insights. Its scope extends from established analytics platforms used in research to emerging AI-driven solutions that support personalised healthcare, accelerate drug development, and advance understanding of complex diseases.
Competitive Landscape
Which are the Leading Players in the AI Multi-Omics Analytics Market?
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- SOPHiA GENETICS SA
- DNAnexus, Inc.
- Tempus AI, Inc.
- Owkin, Inc.
- Recursion Pharmaceuticals, Inc.
- Athos Therapeutics, Inc.
Driver
Growing Demand for Precision Medicine and AI-Driven Drug Discovery
The growing need for precision medicine, personalised healthcare, and faster drug discovery is driving more organisations to use AI-powered multi-omics analytics. These AI tools help researchers combine and analyse data from genomics, transcriptomics, proteomics, metabolomics, and epigenomics. This makes it easier to find disease mechanisms, discover new biomarkers, and understand how patients respond to treatments. Machine learning and deep learning algorithms can process complex biological data more efficiently, helping pharmaceutical and biotech companies develop drugs and identify new treatment targets. As a result, investments in biomedical research, computational biology, and personalised medicine are driving growth in the AI multi-omics analytics market.
Restraint/Challenge
High Data Complexity, Integration Challenges, and Implementation Costs
A major challenge in the AI multi-omics analytics market is integrating and interpreting large, complex datasets from different omics technologies. Differences in data formats, measurement methods, quality, and biological features can affect the accuracy and reliability of results. Building advanced AI platforms also requires strong computing resources, skilled experts, and high-quality training data. Concerns about data privacy, lack of standardisation, and the need to confirm AI findings in real-world research and clinical settings can slow down adoption, especially for smaller research groups and healthcare organisations.
Software Platforms Segment is Expected to Drive the AI Multi-Omics Analytics Market
Software platforms are expected to play a major role in the AI multi-omics analytics market because more people need tools that can handle, combine, visualise, and interpret complex biological data. These platforms help researchers examine different omics data types, identify molecular links, discover biomarkers, and support drug discovery and precision medicine. Machine learning, deep learning, cloud computing, and improved data visualisation are making analysis faster and easier to scale. Increased investment in life sciences and the shift to digital pharmaceutical research are also driving demand for AI-powered multi-omics software platforms.
Machine Learning Segment is Expected to Hold a Significant Share of the AI Multi-Omics Analytics Market
Machine learning is expected to make up a large part of the AI multi-omics analytics market because it is widely used to analyse complex biological data and find patterns related to diseases, treatment responses, and molecular interactions. These algorithms can bring together genomics, transcriptomics, proteomics, and metabolomics data to help identify biomarkers, classify diseases, and prioritise drug candidates. Machine learning is useful in pharmaceutical research, biotechnology, and clinical studies for finding insights in large biological datasets. Ongoing improvements in predictive modelling and automated data analysis are likely to increase the use of machine learning technologies.
Why North America Leads the AI Multi-Omics Analytics Market?
North America is expected to maintain a leading position in the AI multi-omics analytics market, supported by its established biotechnology and pharmaceutical industries, advanced research infrastructure, and strong investments in artificial intelligence and genomics. The region is home to leading life sciences companies, tech developers, research institutions, and healthcare organisations that increasingly use AI in biomedical research.
Partnerships among pharmaceutical companies, biotech firms, and AI providers are accelerating the development and launch of multi-omics analytics solutions. Ongoing funding for precision medicine, cancer research, and drug discovery should help the market grow in this region.
Key Development
• In January 2026, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to develop AI-based solutions and laboratory automation capabilities, aiming to improve laboratory accuracy, speed, and workflow efficiency.
• In May 2026, DNAnexus announced new AI-driven capabilities and solution packages for precision health, strengthening its platform for analyzing complex omics data and supporting the development and deployment of AI models in biomedical research.
AI Multi-Omics Analytics Market Report Scope:
| Report Attribute | Specifications |
| Market size value in 2025 | USD 0.99 Bn |
| Revenue forecast in 2035 | USD 11.67 Bn |
| Growth Rate CAGR | CAGR of 28.2% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Offering, Omics Data Type, AI Technology, Application, End User and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., SOPHiA GENETICS SA, DNAnexus, Inc., Tempus AI, Inc., Owkin, Inc., Recursion Pharmaceuticals, Inc., Athos Therapeutics, Inc. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentations AI Multi-Omics Analytics Market:
AI Multi-Omics Analytics Market by Offering -
- Software Platforms
- Analytics Services
AI Multi-Omics Analytics Market by Omics Data Type-
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Epigenomics
- Others
AI Multi-Omics Analytics Market by Application -
- Drug Discovery and Development
- Biomarker Discovery
- Clinical Diagnostics and Precision Medicine
- Others
AI Multi-Omics Analytics Market by AI Technology -
- Machine Learning
- Deep Learning
- Others
AI Multi-Omics Analytics Market by End User -
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Hospitals and Clinical Laboratories
- Contract Research Organizations (CROs)
- Others
AI Multi-Omics Analytics Market by Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East and Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
AI Multi-Omics Analytics Market Size is valued at USD 0.99 Bn in 2025 and is predicted to reach USD 11.67 Bn by the year 2035
The AI Multi-Omics Analytics Market is expected to grow at a 28.2% CAGR during the forecast period for 2026 to 2035
Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., SOPHiA GENETICS SA, DNAnexus, Inc., Tempus AI, Inc., Owkin, Inc., Recursion Pharmaceuticals, Inc., Athos Therapeutics, Inc. and Others.
AI Multi-Omics Analytics Market is segmented into Offering, Omics Data Type, AI Technology, Application, End User and Other.
North America region is leading the AI Multi-Omics Analytics Market.